CorrectSequence Therapeutics (Correctseq) aims to use our innovative base editing technology to help people with severe diseases.
We have developed multiple base editing systems and our base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Our base editing studies were published in high-profile scientific journals including Nature Biotechnology, Nature Cell Biology, Nature Structural & Molecular Biology, Cell Research and Cell Reports.
Our goal is to discover, develop, manufacture, and commercialize curative genetic medicines for various diseases. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, and infectious diseases are well underway. We have set up R&D and manufacturing centers in Shanghai, as well as the regulatory and clinical center in China Central Place, Beijing. Our world-class R&D laboratory, CMC process development laboratory and cGMP manufacturing facility guarantee the rapid translation and application of our innovative research.
We focus on biotechnology innovation, research and development and are committed to providing efficient, reliable and safe solution for unmet medical needs.
CorrectSequence Therapeutics has gathered dozens of outstanding biomedical experts from the fields of R&D, new drug development, CMC development, clinical operation, quality, etc. The management team and R&D team have more than 10 years industrial experience, with more than 40% of the staff holding master degrees.
Staffs of our management team and R&D team come from well-known domestic and international pharmaceutical companies, research institutions and drug regulatory authorities, such as USA FDA, Merck (MSD US), Pfizer (US), Roche China, Novartis China, Henlius, Luye Pharma, Sinopharm, WuXi Biologics, WuXi AppTech, JW Therapeutics, Hengrui, Innovent, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, etc. We have cross-field drug R&D experience with cancer, genetic disease, liver disease, blood disease, infectious disease, rare disease, mRNA therapy, CAR-T therapy, TCR-T therapy, monoclonal antibody therapy, stem cell therapy and tumor immunotherapy, etc.
Industrial Experience
10 Years+
Management Team and R&D Team
Proportion of M.D.
40 %+
Management Team and R&D Team
Xiaodun (Susan) Mou, Ph.D.
Chief Executive Officer
Guang Gao, Ph.D.
Distinguished Quality Adviser
Jia Chen, Ph.D.
Distinguished Scientific Adviser
Li Yang, Ph.D.
Distinguished Scientific Adviser
Hao Yin, Ph.D.
Distinguished Scientific Adviser
Bei Yang, Ph.D.
Distinguished Scientific Adviser
2022.12 tBE (transformer Base Editor) won the 19th People's Ingenuity Award
2022.12 2022 Science and technology excellence Award of Jiading District, Shanghai
2022.11 Dr. Xiaodun Mou was Selected as the Annual Influential Enterprise Leaders of Chinese CGT Field in 2022
2022.10 Venture Capital Star of Shanghai Entrepreneurs Association & Simbay Park
2022.09 2022 Biomedical "Rising Star" in First Season
2022.06 Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields (VBDATA.CN)
2022.06 2022 Top 50 Biotech Innovation Companies (KPMG)
2022.02 TOP 50 Innovation and Development Companies of 2022 Jiading District’s Stabilizing Business and Promoting Investment project
2022.01 Professor Jia Chen was Selected as "Outstanding Innovation and Entrepreneurial Talent of Zhangjiang”
2021.12 Top 50 Most Innovative Companies of Chinese Biomedicine in 2021
2021.06 Excellent Roadshow Project of the 2nd Annual Meeting of Chinese Society of Cell Therapy of Zhangjiang International Summit on Cell Therapy Industry
2020.12 The first prize of the 3rd Jiading District Entrepreneurship Competition in 2020
2020.12 2020 Jiading District Science and Technology Innovation Award
(arranged by alphabetic order)